Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent-Reference-Cited by-同舟云学术

Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent

Published:2021-01 Issue: Volume:92 Page:171-183
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Feng Yutian,Zhou Zhengyuan,McDougald Darryl,Meshaw Rebecca L.,Vaidyanathan Ganesan,Zalutsky Michael R.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference60 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

3. ErbB receptors: directing key signaling networks throughout life;Holbro;Annu Rev Pharmacol Toxicol,2004

4. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer;Rasaneh;Nucl Med Biol,2009

5. H4octapa-trastuzumab: an acyclic chelator-immunoconjugate with superior properties to DOTA for in-111/Lu-177 imaging and therapy;Price;J Nucl Med,2013

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nanobody inhibitor of Fascin-1 actin-bundling activity and filopodia formation;Open Biology;2024-03

2. A new strategy for facile and rapid separation of astatine-211 from nitric acid medium;Separation and Purification Technology;2024-02

3. Non-traditional approaches for control of antibiotic resistance;Expert Opinion on Biological Therapy;2023-11-02

4. Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins;Journal of the American Chemical Society;2023-08-08

5. Reviving a Classic Antigen with a Cutting-Edge Approach: Nanobodies for HER2+ Breast Cancer;Pharmaceuticals;2023-05-26